Zanubrutinib
Second-generation selective BTK inhibitor
- Response rate
- ~95% ORR; 36% VGPR+CR
- Onset
- Weeks
- Route
- Oral 160mg BID or 320mg daily
- Line
- 1st
- IgM effect
- Significant reduction
Evidence summary
Next-generation BTK inhibitor with greater selectivity for BTK. The ASPEN phase III trial demonstrated comparable efficacy to ibrutinib with significantly improved safety: less atrial fibrillation (7.9% vs 23.5%), less hypertension, less diarrhea. Currently recommended as preferred first-line BTK inhibitor by Mayo Clinic guidelines.
Molecular targets (1)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| BTK (Bruton's Tyrosine Kinase) | Key signaling kinase downstream of MYD88 | Constitutively activated | established |